ARDELYX, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARDELYX, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.68M, a 70.04% increase year-over-year.
- ARDELYX, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $4.70M, a 906.42% increase year-over-year.
- ARDELYX, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $557.00K, a 8.99% decline year-over-year.
- ARDELYX, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $2.11M, a 39.99% increase year-over-year.
- ARDELYX, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $4.12M, a 30.25% decline from fiscal 2024.
- ARDELYX, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $5.91M, a 1519.45% increase from fiscal 2023.
- ARDELYX, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $365.00K, a 5114.29% increase from fiscal 2022.
- ARDELYX, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $7.00K, a 98.80% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.68M 10-Q · filed 2026-08-06 | $9.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.70M 10-Q · filed 2026-04-30 | $8.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $557.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $4.12M 10-K · filed 2026-02-19 |
| 2025-09-30 | $2.11M 10-Q · filed 2025-10-30 | $4.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $988.00K 10-Q · filed 2026-08-06 | $3.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $467.00K 10-Q · filed 2026-04-30 | $4.20M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $612.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $5.91M 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.51M 10-Q · filed 2025-10-30 | $5.41M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $1.61M 10-Q · filed 2025-08-04 | $3.94M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $2.18M 10-Q · filed 2025-05-01 | $2.49M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $365.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | $40.00K 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $149.00K 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $62.00K 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $7.00K 10-K · filed 2025-02-20 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $584.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $21.00K 10-Q · filed 2022-11-03 | $845.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $543.00K 10-Q · filed 2022-08-04 | $1.16M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $20.00K 10-Q · filed 2022-05-05 | $824.00K derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.02M 10-K · filed 2023-03-02 |
| 2020-09-30 | $339.00K 10-Q · filed 2021-11-12 | $916.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $204.00K 10-Q · filed 2021-08-13 | $590.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $216.00K 10-Q · filed 2021-05-06 | $391.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $178.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $13.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $5.00K 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $2.00K 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $53.77M 10-K · filed 2021-03-08 | |
| 2017-12-31 | $9.59M 10-K · filed 2020-03-06 | |
| 2016-12-31 | $55.00K 10-K · filed 2019-03-06 | |
| 2015-12-31 | $111.00K 10-K · filed 2018-03-14 | |
| 2014-12-31 | $238.00K 10-K · filed 2017-02-17 | |
| 2013-12-31 | $125.00K 10-K · filed 2016-03-04 | |
| 2012-12-31 | $175.00K 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |